Innovative Topical Antifungal
description
Transcript of Innovative Topical Antifungal
![Page 1: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/1.jpg)
INNOVATIVE TOPICAL ANTIFUNGAL
![Page 2: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/2.jpg)
ONYCHOMYCOSIS• Fungal Infection of nails and toes• Caused by dermatophytes• Infect the nail plate and nail bed• Causes nails deformation,
discoloration and thickening• Causes pain and social
embarrassment
![Page 3: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/3.jpg)
ONYCHOMYCOSIS MARKET• 35 million people in the US• 95% of Onychomycosis infections
are of toenails• 47% of patients not receiving
treatement
![Page 4: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/4.jpg)
US ONYCHOMYCOSIS MARKET
Receiving treatement
53%
No treatement 47%
US Onychomycosis Market
![Page 5: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/5.jpg)
TREATMENT OPTIONS• Nail debridement• Oral medication (systemic)• Topical medication• Combination of nail debridement
and medication
![Page 6: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/6.jpg)
LAMISIL• Worldwide sales $1.2 Billion-2004• 1.4 Million new prescriptions per
year in the US-2010• Efficacy rate = 38% (Standard of
Care)
![Page 7: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/7.jpg)
LAMISIL LIMITATIONS• Safety concerns : Liver Toxicity• Multiple drug-drug interactions and
multiple drug-food interactions• Efficacy rate only 38% with high
relapse rate leading to patients redoing other courses of treatement
• Multiple doctor visits and follow-ups
![Page 8: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/8.jpg)
TOPICAL TREATEMENT• Creams and solutions are not
effective (cannot penetrate the nail structure)
• Only Penlac ® Lacquer is approved for treatement
• US sales $125 Million in 2002• 350 000 new prescriptions /year-
2010
![Page 9: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/9.jpg)
PENLAC LIMITATIONS• Low labelled efficacy (5.5 - 8.5%)
• Need to use nail polish remover before applying the next coat
![Page 10: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/10.jpg)
CONCLUSION• Onychomycosis market is still in
search for a topical product that can penetrate the nail plate and provide :
100% clear nailInfection cure
![Page 11: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/11.jpg)
INTRODUCING
RAF02
![Page 12: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/12.jpg)
RAF02 FEATURESTopical liquid formulationNon-irritant High effective penetration to the nail bed
Stable at room temperature
![Page 13: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/13.jpg)
RAF02 FEATURES (CONT.) Dissolves high % of Active
Antifungal Sustained release formulation Protective coat No need to use nail polish
remover
![Page 14: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/14.jpg)
RAF02 FEATURES (CONT.) Provides a protective
membrane Preservative free Clinically tested with
higher cure rates Ingredients FDA approved
![Page 15: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/15.jpg)
RAF02 CLINICAL EXPERIENCE12 patients with fungal infection of
the nail and toenail have used RAF02
100% cure rate
![Page 16: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/16.jpg)
RAF02 ROAD MAPFormulation Design ✔Research & Development ✔Clinical Testing ✔Further Research &
Development✔Application for a Patent ✔Strategic Partnering
![Page 17: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/17.jpg)
RAF02 ROAD MAP (CONT.) Venture Capital Financing FDA approved Clinical
Trial FDA Registration Marketing $Sales
![Page 18: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/18.jpg)
RAF02 CLINICAL RESULTS
Before Treatment with RAF02
![Page 19: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/19.jpg)
RAF02 CLINICAL RESULTS
After Treatment with RAF02
![Page 20: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/20.jpg)
RAF02 CLINICAL RESULTS
Before Treatment with RAF02
![Page 21: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/21.jpg)
RAF02 CLINICAL RESULTS
After Treatment with RAF02
![Page 22: Innovative Topical Antifungal](https://reader036.fdocuments.in/reader036/viewer/2022062400/568168f6550346895de003d2/html5/thumbnails/22.jpg)
RAF02
Contact Information:Samy Saad, R.Ph.Managing DirectorRichpoint Pharma10815 Yonge Sreet, Richmond HillOntario L4C3E3 Canada(416) [email protected]